A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating The Safety And Activity of DCDT2980S in Combination with Rituximab or DCDS4501A in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Description: 

The primary objectives of this study are to assess the safety and tolerability of the combination of DCDT2980S and rituximab administered to patients with relapsed or refractory follicular Non-Hodgkins Lymphomaand DLBCL.

Study Number: 

PH 230212

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01691898

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.